Bastide Le Confort Médical (BLC) Q3 2025 earnings summary

Executive summary

• Nine-month revenue reached €419.4 million, up 8.4% year-over-year, with organic growth of 8.1%.

• Q3 revenue was €144.2 million, up 7.9% year-over-year, or 7.7% on an organic basis.

• Home healthcare services grew 10.4% organically, while Homecare activities rose 3.2% in Q3.

• 2024-2025 revenue and margin targets are confirmed, reflecting continued strong business momentum.

Financial highlights

• Q1 revenue: €133.8 million (+9.1% year-over-year); Q2: €141.4 million (+8.1%); Q3: €144.2 million (+7.9%).

• Nine-month revenue: €419.4 million, up from €399.7 million (published) and €387.1 million (adjusted) last year.

• Homecare revenue for nine months: €150.8 million, up 4.2% like-for-like.

• Respiratory business revenue: €156.2 million, up 13.5% (12.9% organic), now 58% of homecare services.

• Nutrition-Perfusion-Stomatherapy-Diabetes revenue: €112.3 million, up 7.3%.

Outlook and guidance

• 2024-2025 targets reaffirmed: at least €560 million in revenue and operating margin before non-recurring items of at least 9.1%.

• Additional growth expected from new contracts in Canada and the UK.

• Focus on debt reduction and improved leverage through earnings growth and asset disposals.